Pharmaceuticals

Technological Advancements Shaping the Biologics CDMO Market

March 18, 2026March 18, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Biologics CDMO Market At The End Of The 2026–2030 Forecast Period?

The biologics cdmo market size has expanded significantly in recent years. It is projected to grow from $24.15 billion in 2025 to $27.56 billion in 2026, achieving a compound annual growth rate (CAGR) of 14.1%. This historical growth can be attributed to factors such as a rise in biologics research, advancements in cell culture technologies, the increasing prevalence of chronic diseases, the growth of biosimilar pipelines, and government support for biopharma manufacturing.

The biologics cdmo market is projected to expand significantly over the coming years, reaching $48.07 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 14.9%. This anticipated expansion is driven by several factors, including a significant rise in gene and cell therapy development, the integration of automation and robotics within CDMO operations, the broadening of global biologics production capabilities, an uplift in precision medicine investments, and an escalating need for economical biologics. Key developments anticipated during this timeframe involve the broadening of biologics cdmo service offerings, an increase in mammalian cell-based manufacturing, a greater reliance on outsourcing for gene therapy production, the implementation of sophisticated bioprocessing methods, and an elevated call for biosimilars.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=14056&type=smp

What Primary Drivers Are Shaping The Development Of The Biologics CDMO Market?

The growing requirement for cell and genetic therapy is anticipated to boost the expansion of the biologic CDMO market. These therapies represent cutting-edge medical strategies employing living cells or genetic material to target fundamental disease causes at the cellular or genetic level, offering potential cures for conditions otherwise challenging or impossible to treat with conventional drugs. The increasing interest in cell and gene therapy stems from their capacity to provide novel treatments by addressing underlying genetic or cellular issues. Biologic CDMOs offer specialized knowledge in managing living cells, viral vectors, and genetic material, ensuring the secure and effective manufacture of cell and gene therapies. They also support biopharmaceutical firms in overcoming regulatory hurdles and technical complexities, thereby enabling the transition from research to clinical use. For example, in March 2024, IQVIA Holdings Inc., a US-based provider of advanced analytics, technology solutions, and clinical research services for the life sciences and healthcare industries, reported that global expenditure on cell and gene therapies reached $5.9 billion in 2023, marking a 38% rise from 2022. Consequently, the escalating demand for cell and genetic therapy is fueling the expansion of the biologic CDMO market.

What Segment Types Make Up The Biologics CDMO Market?

The biologics cdmo market covered in this report is segmented –

1) By Cell Type: Mammalian, Non-Mammalian

2) By Product Type: Biologics, Biosimilars

3) By Service Type: Drug Substance Manufacturing, Drug Product (Fill–Finish) Manufacturing, Process Development, Analytical & Quality Testing Services

Subsegments:

1) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cells

2) By Non-Mammalian: Yeast Cells, Bacterial Cells, Insect Cells, Other Non-Mammalian Cells

Which Market Trends Are Creating New Opportunities In The Biologics CDMO Market?

Leading companies operating in the biologics CDMO market are actively developing technologically advanced solutions, such as novel cell lines, to significantly enhance the efficiency and capabilities of biopharmaceutical development and manufacturing. This technology is instrumental in producing therapeutic antibodies with elevated potency, effectively addressing challenges encountered in immunotherapy research and development. For example, in November 2023, Lonza Group, a Switzerland-based manufacturing company focused on the pharmaceutical and biotechnology sectors, introduced its GS Effex cell lines. These lines are specifically engineered to produce antibodies that are 100% free of fucose, a particular sugar molecule, and exhibit increased potency without detriment to other performance characteristics. This development helps to overcome immunotherapy research and development hurdles concerning the requirement for more potent antibody therapeutics. The solution provided is a stable, scalable, and highly productive cell line, offering a complete pathway for therapeutic development, from initial discovery-stage research through to commercial-scale manufacturing.

Who Are The Key Players Driving Competition In The Biologics CDMO Market?

Major companies operating in the biologics cdmo market are Lonza Group Ltd, Samsung Biologics Co Ltd, WuXi Biologics Cayman Inc, Catalent Inc, Thermo Fisher Scientific Inc, Boehringer Ingelheim International GmbH, Emergent BioSolutions Inc, Grifols SA, AbbVie Inc, Novartis AG, Sandoz International GmbH, Fujifilm Holdings Corporation, AGC Inc, JSR Corporation, Shenzhen Hepalink Pharmaceutical Co Ltd, Kemwell Biopharma Pvt Ltd, Bora Pharmaceuticals Co Ltd, Binex Co Ltd, 3P Biopharmaceuticals SLU, Cytovance Biologics

Read the full biologics cdmo market report here:

https://www.thebusinessresearchcompany.com/report/biologics-cdmo-global-market-report

How Does The Biologics CDMO Market Perform Across Major Global Regions?

North America was the largest region in the biologics CDMO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics cdmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Biologics CDMO Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=14056&type=smp

Browse Through More Reports Similar to the Global Biologics CDMO Market 2026, By The Business Research Company

Biologics Cdmo Market Report 2026

https://www.thebusinessresearchcompany.com/report/biologics-cdmo-global-market-report

Biologics Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/biologics-testing-global-market-report

Biologics Contract Development Market Report 2026

https://www.thebusinessresearchcompany.com/report/biologics-contract-development-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795